0001104659-20-076542.txt : 20200624 0001104659-20-076542.hdr.sgml : 20200624 20200624194853 ACCESSION NUMBER: 0001104659-20-076542 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200617 FILED AS OF DATE: 20200624 DATE AS OF CHANGE: 20200624 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KENNEDY WILLIAM JAMES CENTRAL INDEX KEY: 0001448888 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 20986762 MAIL ADDRESS: STREET 1: C/O XTL BIOPHARMACEUTICALS LTD STREET 2: 711 EXECUTIVE BLVD., SUITE Q CITY: VALLEY COTTAGE STATE: NY ZIP: 10989 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10014 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 4 1 tm2022959d1_4.xml OWNERSHIP DOCUMENT X0306 4 2020-06-17 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001448888 KENNEDY WILLIAM JAMES 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 1 0 0 0 COMMON STOCK 2020-06-17 4 S 0 7745 18.27 D 94633 D COMMON STOCK 2020-06-22 4 A 0 15000 0 D 109633 D In connection with the vesting of 15,000 shares on June 16, 2020, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Kennedy's tax obligations. Mr. Kennedy had no discretion with respect to such sale, which was transacted automatically in accordance with the Company's corporate policies regarding the vesting of restricted stock. Represents the weighted average sales price. The range of prices for such transaction was $18.20 to $18.36. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Includes shares of restricted Common Stock, which vest over various time periods. Reflects a grant of restricted shares that will vest on June 22, 2023. /s/ William Kennedy 2020-06-24